StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.04−0.01 (-0.95%)

Close on Nov 20, 2026Market cap $109.58MP/E –Yield –

ProQR Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ProQR Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -€50.16M. For fiscal 2025 it was -€53.81M. The highest annual figure on record is €20.18M in fiscal 2023.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€53.81M–
FY2024Dec 31, 2024-€37.81M-287.4%
FY2023Dec 31, 2023€20.18M–
FY2022Dec 31, 2022-€69.22M–
FY2021Dec 31, 2021-€26.50M–
FY2020Dec 31, 2020-€47.98M–
FY2019Dec 31, 2019-€44.55M–
FY2018Dec 31, 2018-€28.81M–
FY2017Dec 31, 2017-€35.07M–
FY2016Dec 31, 2016-€36.76M–
FY2015Dec 31, 2015-€25.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€12.56M–
Q1 FY2026Mar 31, 2026-€11.31M–
Q4 FY2025Dec 31, 2025-€13.88M–
Q3 FY2025Sep 30, 2025-€12.40M–
Q2 FY2025Jun 30, 2025-€11.50M–
Q1 FY2025Mar 31, 2025-€16.02M–
Q4 FY2024Dec 31, 2024-€9.48M–
Q3 FY2024Sep 30, 2024-€5.94M–
Q2 FY2024Jun 30, 2024-€6.52M–
Q1 FY2024Mar 31, 2024-€15.86M-135.6%
Q4 FY2023Dec 31, 2023-€5.92M–
Q3 FY2023Sep 30, 2023-€7.85M–
Q2 FY2023Jun 30, 2023-€10.64M–
Q1 FY2023Mar 31, 2023€44.59M–
Q4 FY2022Dec 31, 2022-€17.82M-600.6%
Q3 FY2022Sep 30, 2022-€15.61M–
Q2 FY2022Jun 30, 2022-€15.08M–
Q1 FY2022Mar 31, 2022-€20.71M–
Q4 FY2021Dec 31, 2021€3.56M–
Q3 FY2021Sep 30, 2021-€8.23M–
Q2 FY2021Jun 30, 2021-€10.03M–
Q1 FY2021Mar 31, 2021-€11.79M–
Q4 FY2020Dec 31, 2020-€11.87M–
Q3 FY2020Sep 30, 2020-€10.07M–
Q2 FY2020Jun 30, 2020-€10.83M–
Q1 FY2020Mar 31, 2020-€15.21M–
Q4 FY2019Dec 31, 2019-€12.20M–
Q3 FY2019Sep 30, 2019-€8.80M–
Q2 FY2019Jun 30, 2019-€10.96M–
Q1 FY2019Mar 31, 2019-€12.59M–
Q4 FY2018Dec 31, 2018-€9.13M–
Q3 FY2018Sep 30, 2018-€4.36M–
Q2 FY2018Jun 30, 2018-€5.61M–
Q2 FY2017Jun 30, 2017-€9.89M–

More ProQR Therapeutics figures

See a number that looks wrong?